Concerns Grow as Class Action Filed Against PROCEPT BioRobotics Corporation Over Securities Fraud Allegations

Investor Alert: Class Action Lawsuit Filed Against PROCEPT BioRobotics Corporation

In a significant development, Pomerantz LLP has filed a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) following troubling reports about the company's financial practices and sales figures. This lawsuit has arisen as investors express grave concerns regarding potential securities fraud and business misconduct by the company and its executives.

The class action invites affected investors to come forward and engage with Pomerantz LLP, emphasizing the urgency of the situation as deadlines approach. Investors who suffered losses from their investment in PROCEPT are urged to contact the firm by email or phone to participate in the proceedings.

Company Performance Under Scrutiny

The scrutiny of PROCEPT's performance began after the company reported notably low sales of its surgical handpieces in recent quarters. In August 2025, PROCEPT revealed that it sold just 12,750 units during its second fiscal quarter, a figure that fell significantly short of the market’s expectations. During the earnings call, CFO Kevin Waters predicted a slight increase in sales for the following quarter, estimating 13,350 units, yet this was still below the consensus estimate of over 13,840 units. The company's hesitance to revise sales estimates raised alarms among stakeholders.

Further complications arose when Reza Zadno, the then-CEO of PROCEPT, announced the removal of the Chief Commercial Officer role, a decision taken purportedly to enhance their commercial execution strategy. This announcement coincided with a sharp decline of approximately 16% in the stock price over two days, indicating that investor confidence was faltering.

Additional Revelations and Sales Adjustments

The situation continued to deteriorate following the company's third-quarter earnings announcement on November 4, 2025. PROCEPT only managed to sell 13,225 handpieces, missing sales guidance and leading to further adjustments in their annual sales projections. CFO Waters disclosed a reduction in the annual guidance from 53,000 units to 52,000 units, a strategy attributed to the need for inventory optimization.

Admitting to flaws in inventory management, CEO Larry L. Wood indicated that customer inventory levels were not being adequately controlled, resulting in excess stock held by some clients. This lack of oversight, coupled with declining sales figures, further undermined investor trust in the company's leadership and operations.

Major Stock Price Declines Unfold

The stock price dropped by another 10% following this disheartening update, a clear sign that investor sentiment was again shaken. By February 25, 2026, when the company released its fourth-quarter results, the situation had worsened. During a pivotal earnings release, PROCEPT disclosed a staggering decline in handpiece sales, plummeting to just 9,400 units, a nearly 30% drop from the previous quarter's figures.

Such drastic declines led to an even more pronounced downturn, with the stock falling over 18% in light of these alarming updates. Investors had become increasingly wary of the company's long-term viability, prompting many to consider legal action.

Why a Class Action?

The concerns laid out in the class action encompass a broader array of issues relating to potential misconduct in securities dealings and misleading business practices. Investors who purchased PROCEPT securities during the class period are encouraged to act quickly, as they possess until September 22, 2026, to petition the court for appointment as Lead Plaintiff. Affected individuals can obtain a copy of the complaint from Pomerantz LLP’s website, providing a resource for those seeking to understand their rights and options moving forward.

Pomerantz LLP has a longstanding reputation in securities litigation, having fought for the rights of investors since its establishment over 85 years ago. Notably, the firm has successfully recovered multi-million dollar settlements for victims of corporate malpractice. Investors finding themselves in this challenging position should not hesitate to reach out for professional assistance.

This class action represents not only an opportunity for recourse but also a pivotal moment for stakeholders aiming to hold PROCEPT BioRobotics accountable for its alleged practices. As the legal proceedings unfold, the firm’s history of robust advocacy will likely play a crucial role in shaping the outcome of this case.